Non-Myloablative Conditions Using Penostatin, Rituximab, Denileukin Diftitox (Ontak) and Allogeneic Natural Killer Cells for Patients with Refractory Lymphoid Malignancies
|Effective start/end date||8/1/09 → 12/31/13|
- EISAI MEDICAL RESEARCH INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.